Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02773082 · ClinicalTrials.gov registry record · NA
DBS for Obsessive-Compulsive Disorder
A NA study of Obsessive Compulsive Disorder (OCD), sponsored by Northwell Health.
- Recruiting
- Registry status
- NA
- Development phase
- 50
- Enrollment target
- 1
- Study location
NCT02773082 is a NA study of Obsessive Compulsive Disorder (OCD) that is actively recruiting participants, run by Northwell Health. The registered enrollment target is 50 participants, below the 240-participant average among 12 other Obsessive Compulsive Disorder (OCD) trials with a reported enrollment target (79% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02773082, a NA study of Obsessive Compulsive Disorder (OCD), is actively recruiting participants, sponsored by Northwell Health.
- RECRUITING
- Registry status
- NA
- Development phase
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
There are two primary approaches to the treatment of OCD, pharmacotherapy and cognitive behavior therapy (CBT). Lack of therapeutic success with one approach leads to trials of the alternative approach or a combination of the two. A rarely used third therapy approach, appropriate for only the most severely afflicted and treatment resistant patients, is neurosurgical ablation of certain brain regions involved in mood and anxiety. The neurosurgical ablation procedures are irreversible in nature, and involve the destruction of specific volumes of brain tissue through various controlled means. Surgical procedures include cingulotomy, subcaudate tractotomy, limbic leucotomy which is a combination of the first two procedures and capsulotomy. DBS therapy is an alternative to neurosurgical procedures, specifically anterior capsulotomy, for patients with chronic, severe OCD which has proven resistant to primary pharmacological and/or behavior therapy options. Results from 26 severe, treatment-resistant OCD patients treated with DBS at four collaborating centers, three in the US, and one in Europe are summarized in great detail in pages 12-22 of the provided/attached "Reclaim Summary of Safety and Probable Benefit."
Conditions Studied
Interventions
- DEVICE Reclaim™ DBS Therapy
Study Locations (1)
New York
- Zucker Hillside Hospital - Queens
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2024-07-06 |
| Est. Completion | 2030-01-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02773082
The ClinicalTrials.gov registry entry for NCT02773082 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 240-participant average among 12 other Obsessive Compulsive Disorder (OCD) trials with a reported enrollment target (79% lower). The listed sponsor is Northwell Health, which has 370 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Obsessive Compulsive Disorder (OCD) appearing as the primary indexed condition, and to 1 intervention - of which Reclaim™ DBS Therapy is the first listed.
NCT02773082 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT02773082 about?
NCT02773082 is a clinical study titled "DBS for Obsessive-Compulsive Disorder". There are two primary approaches to the treatment of OCD, pharmacotherapy and cognitive behavior therapy (CBT). Lack of therapeutic success with one approach leads to trials of the alternative approach or a combination of the two. A rarely used third therapy approach, appropriate for only the most s...
What is the current status of trial NCT02773082?
This trial is currently recruiting. It is a NA study. The enrollment target is 50 participants. The study started on 2024-07-06. Estimated completion is 2030-01-01.
What conditions does trial NCT02773082 study?
This clinical trial studies the following conditions: Obsessive Compulsive Disorder (OCD).
What interventions are being tested in trial NCT02773082?
The interventions under investigation include: Reclaim™ DBS Therapy (DEVICE).
Who is sponsoring clinical trial NCT02773082?
This trial is sponsored by Northwell Health, which has 370 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02773082 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obsessive Compulsive Disorder (OCD)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Transcranial Direct Current Stimulation and Extinction in Obsessive Compulsive Disorder
RECRUITING · NA
-
ERP to Improve Functioning in Veterans With OCD
RECRUITING · NA
-
Connectomic Deep Brain Stimulation for Obsessive Compulsive Disorder
RECRUITING · NA
-
Stepped Care Treatment for Anxiety Resilience
RECRUITING · NA
-
Implementing Team-Based Treatment for Pediatric Anxiety in Community Mental Health Settings
RECRUITING · NA
-
Comparative Effectiveness of Internet-based Versus Parent-Coached Cognitive-Behavioral Therapy For Children and Adolescents With Anxiety and OCD
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.